12 results on '"Timmers C"'
Search Results
2. The β-glucuronyl-based prodrug strategy allows for its application on β-glucuronyl-platinum conjugates
- Author
-
Tromp, Reynier A., van Boom, Stella S.G.E., Marco Timmers, C., van Zutphen, Steven, van der Marel, Gijsbert A., Overkleeft, Herman S., van Boom, Jacques H., and Reedijk, Jan
- Subjects
- *
TUMORS , *DRUG side effects , *GLUCURONIDASE , *THERAPEUTICS - Abstract
The use of platinum drugs in antitumour therapy is well established. An important drawback of these chemotherapeutics is the lack of selectivity for tumour cells, usually resulting in severe toxic side effects. A glucuronyl-platinum conjugate was designed and synthesised to test the compatibility of platinum compounds with β-glucuronidase-based prodrug therapy. Instantaneous cleavage of the β-glucuronic bond in the glucuronyl-platinum conjugate was observed upon addition of β-glucuronidase resulting in PtII(dach)(4-hydroxybenzylmalonate) and glucuronic acid. [Copyright &y& Elsevier] more...
- Published
- 2004
- Full Text
- View/download PDF
Catalog
3. Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist.
- Author
-
Karstens, Willem F.J., M.B.P. Menge, Wiro, Martens, Gijs, op het Veld, Sanne J.N., Th.H. van Eupen, Jacobus, Demon, Marco, van Achterberg, Tanja A.E., Arisse-Thijssen, Monica J., Santegoeds-Lenssen, Ellen W.H., van der Lee, Miranda M.C., Ubink, Ruud, Arends, Roel J., Sesink, Aloys, Blomenröhr, Marion, and Marco Timmers, C. more...
- Subjects
- *
THYROTROPIN receptors , *SMALL molecules , *THYROID gland , *HORMONE synthesis , *THYROID hormone receptors , *THYROID hormones - Abstract
[Display omitted] • Discovery of a novel class of thyrotropin receptor antagonists. • A highly potent compound with oral efficacy was identified. • Risk of mutagenicity of compounds strongly reduced. • Efficacy correlates with exposure after oral dosing. The thyrotropin receptor (TSH-R) regulates the thyroid gland and is normally activated by thyrotropin. In patients with Graves' disease, TSH-R is also stimulated by stimulatory TSH-R autoantibodies leading to hyperthyroidism. In this paper, we describe the discovery of SYD5115 (67), a novel small molecule TSH-R antagonist with nanomolar potency. SYD5115 also blocks stimulating antibody induced synthesis of the thyroid hormone thyroxine (T 4) in vivo , after a single oral dose. During optimization, several issues had to be addressed such as the low metabolic stability and the potential mutagenicity of our first series of compounds. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
4. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
- Author
-
Wu, C, Mikhail, S, Wei, L, Timmers, C, Tahiri, S, Neal, A, Walker, J, El-Dika, S, Blazer, M, Rock, J, Clark, D J, Yang, X, Chen, J L, Liu, J, Knopp, M V, and Bekaii-Saab, T
- Subjects
- *
ESOPHAGEAL cancer patients , *PROTEIN-tyrosine kinase inhibitors , *PHARMACODYNAMICS , *VASCULAR endothelial growth factors , *CONFIDENCE intervals , *THROMBOCYTOPENIA - Abstract
Background:Blockade of the vascular endothelial growth factor (VEGF) pathway shows evidence of activity in gastro-oesophageal (GE) and oesophageal cancer. We investigated the efficacy of sunitinib, a multikinase VEGF inhibitor, in patients with relapsed/refractory GE/oesophageal cancer.Methods:This was a single-stage Fleming phase II study. The primary end point was progression-free survival (PFS) at 24 weeks. If five or more patients out of a total of 25 were free of progressive disease at 24 weeks, sunitinib would be recommended for further study. Patients received sunitinib 37.5 mg orally daily and imaged every 6 weeks. Exploratory correlative analysis included serum growth factors, tumour gene expression and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).Results:Twenty-five evaluable patients participated in the study. Progression-free survival at 24 weeks was 8% (n=2 patients; confidence interval (CI): 95% 1.4-22.5%), and the duration of best response for the patients was 23 and 72 weeks. Ten patients (42%) had stable disease (SD) for >10 weeks. Overall response rate is 13%. Median PFS is 7 weeks (95% CI: 5.6-11.4 weeks) and the median overall survival is 17 weeks (95% CI: 8.9-25.3 weeks). Most common grade 3/4 toxicities included fatigue (24%), anaemia (20%) thrombocytopenia (16%), and leucopenia (16%). No patients discontinued therapy due to toxicity. Serum VEGF-A and -C levels, tumour complement factor B (CFB) gene expression, and DCE-MRI correlated with clinical benefit, defined as SD or better as best response.Conclusion:Sunitinib is well tolerated but only a select subgroup of patients benefited. Serum VEGF-A and -C may be early predictors of benefit. On this study, patients with clinical benefit from sunitinib had higher tumour CFB expression, and thus has identified CFB as a potential predictor for efficacy of anti-angiogenic therapy. These findings need validation from future prospective trials. [ABSTRACT FROM AUTHOR] more...
- Published
- 2015
- Full Text
- View/download PDF
5. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth.
- Author
-
Mathsyaraja, H, Thies, K, Taffany, D A, Deighan, C, Liu, T, Yu, L, Fernandez, S A, Shapiro, C, Otero, J, Timmers, C, Lustberg, M B, Chalmers, J, Leone, G, and Ostrowski, M C
- Subjects
- *
COLONY-stimulating factors (Physiology) , *MICRORNA , *METASTASIS , *TUMOR growth , *CANCER prognosis , *CANCER cells , *MACROPHAGES , *CELLULAR signal transduction - Abstract
Metastasis of solid tumors is associated with poor prognosis and bleak survival rates. Tumor-infiltrating myeloid cells (TIMs) are known to promote metastasis, but the mechanisms underlying their collaboration with tumor cells remain unknown. Here, we report an oncogenic role for microRNA (miR) in driving M2 reprogramming in TIMs, characterized by the acquisition of pro-tumor and pro-angiogenic properties. The expression of miR-21, miR-29a, miR-142-3p and miR-223 increased in myeloid cells during tumor progression in mouse models of breast cancer and melanoma metastasis. Further, we show that these miRs are regulated by the CSF1-ETS2 pathway in macrophages. A loss-of-function approach utilizing selective depletion of the miR-processing enzyme Dicer in mature myeloid cells blocks angiogenesis and metastatic tumor growth. Ectopic expression of miR-21 and miR-29a promotes angiogenesis and tumor cell proliferation through the downregulation of anti-angiogenic genes such as Col4a2, Spry1 and Timp3, whereas knockdown of the miRs impedes these processes. miR-21 and miR-29a are expressed in Csf1r+ myeloid cells associated with human metastatic breast cancer, and levels of these miRs in CD115+ non-classical monocytes correlates with metastatic tumor burden in patients. Taken together, our results suggest that miR-21 and miR-29a are essential for the pro-tumor functions of myeloid cells and the CSF1-ETS2 pathway upstream of the miRs serves as an attractive therapeutic target for the inhibition of M2 remodeling of macrophages during malignancy. In addition, miR-21 and miR-29a in circulating myeloid cells may potentially serve as biomarkers to measure therapeutic efficacy of targeted therapies for CSF1 signaling. [ABSTRACT FROM AUTHOR] more...
- Published
- 2015
- Full Text
- View/download PDF
6. 220 (PB100) - Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers.
- Author
-
Wee, S., Ye, M., Lo, Y., Hansbury, M., Shin, N., Weber, M., Roman, V., Huo, L., Skaggs, H., Drake, K., Kapilashrami, K., Stump, K., Yang, J., Chand, S., Timmers, C., Hummel, J., Ye, Y., Zhang, G., Yang, Y.O., and Covington, M. more...
- Subjects
- *
PROTEINS , *CONFERENCES & conventions , *CYCLIN-dependent kinases , *TUMORS - Published
- 2022
- Full Text
- View/download PDF
7. Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor
- Author
-
van Koppen, Chris J., Verbost, Pieter M., van de Lagemaat, Ruud, Karstens, Willem-Jan F., Loozen, Huub J.J., van Achterberg, Tanja A.E., van Amstel, Monique G.A., Brands, Jolanda H.G.M., van Doornmalen, Els J.P., Wat, Jesse, Mulder, Saskia J., Raafs, Bianca C., Verkaik, Saskia, Hanssen, Rob G.J.M., and Timmers, C. Marco more...
- Subjects
- *
ALLOSTERIC regulation , *FOLLICLE-stimulating hormone receptor , *GRANULOSA cells , *CELL differentiation , *FEMALE infertility , *DRUG bioavailability , *ESTRADIOL , *MOLECULAR weights , *THERAPEUTICS - Abstract
Abstract: Follicle-stimulating hormone (FSH) activates FSH receptors (FSHR) in granulosa cells to induce follicle differentiation, growth and estradiol production. FSH is used clinically to treat female infertility and is administered by injection. To increase patient convenience and compliance, compound homogeneity and composition, low molecular weight (LMW), orally bioavailable, FSHR agonists are now being developed to replace FSH. In this study, we present the signaling mechanisms of a newly developed LMW dihydropyridine agonist of the FSHR, Org 214444-0. Org 214444-0 is shown to be a stereoselective, nanomolar potent FSHR agonist and selective over the structurally related LHR and TSHR. Org 214444-0 is an allosteric agonist interacting with the transmembrane region of the FSHR. When co-incubated with FSH, Org 214444-0 augments FSH''s potency in binding (6.5-fold) and adenylyl cyclase/cAMP activation (3.5-fold) in a concentration-dependent manner. Like FSH, Org 214444-0 induces FSHR internalization and is only marginally effective in stimulating phospholipase C. Moreover, Org 214444-0 stimulates cAMP and estradiol production in human granulosa cells in culture and supports the follicular phase in mature female rats. We conclude that Org 214444-0 is a bonafide FSHR agonist. [Copyright &y& Elsevier] more...
- Published
- 2013
- Full Text
- View/download PDF
8. Org 214007-0: A Novel Non-Steroidal Selective Glucocorticoid Receptor Modulator with Full Anti-Inflammatory Properties and Improved Therapeutic Index.
- Author
-
van Lierop, Marie-José C., Alkema, Wynand, Laskewitz, Anke J., Dijkema, Rein, van der Maaden, Hans M., Smit, Martin J., Plate, Ralf, Conti, Paolo G. M., Jans, Christan G. J. M., Timmers, C. Marco, van Boeckel, Constant A. A., Lusher, Scott J., McGuire, Ross, van Schaik, Rene C., de Vlieg, Jacob, Smeets, Ruben L., Hofstra, Claudia L., Boots, Annemieke M. H., van Duin, Marcel, and Ingelse, Benno A. more...
- Subjects
- *
TICK-borne encephalitis viruses , *ARBOVIRUS diseases , *GENETICS , *GENETIC recombination ,CENTRAL nervous system infections - Abstract
Glucocorticoids (GCs) such as prednisolone are potent immunosuppressive drugs but suffer from severe adverse effects, including the induction of insulin resistance. Therefore, development of so-called Selective Glucocorticoid Receptor Modulators (SGRM) is highly desirable. Here we describe a non-steroidal Glucocorticoid Receptor (GR)-selective compound (Org 214007-0) with a binding affinity to GR similar to that of prednisolone. Structural modelling of the GR-Org 214007- 0 binding site shows disturbance of the loop between helix 11 and helix 12 of GR, confirmed by partial recruitment of the TIF2-3 peptide. Using various cell lines and primary human cells, we show here that Org 214007-0 acts as a partial GC agonist, since it repressed inflammatory genes and was less effective in induction of metabolic genes. More importantly, in vivo studies in mice indicated that Org 214007-0 retained full efficacy in acute inflammation models as well as in a chronic collagen-induced arthritis (CIA) model. Gene expression profiling of muscle tissue derived from arthritic mice showed a partial activity of Org 214007-0 at an equi-efficacious dosage of prednisolone, with an increased ratio in repression versus induction of genes. Finally, in mice Org 214007-0 did not induce elevated fasting glucose nor the shift in glucose/glycogen balance in the liver seen with an equi-efficacious dose of prednisolone. All together, our data demonstrate that Org 214007-0 is a novel SGRMs with an improved therapeutic index compared to prednisolone. This class of SGRMs can contribute to effective anti-inflammatory therapy with a lower risk for metabolic side effects. [ABSTRACT FROM AUTHOR] more...
- Published
- 2012
- Full Text
- View/download PDF
9. Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.
- Author
-
van Koppen, Chris J, de Gooyer, Marcel E, Karstens, Willem-Jan, Plate, Ralf, Conti, Paolo GM, van Achterberg, Tanja AE, van Amstel, Monique GA, Brands, Jolanda HGM, Wat, Jesse, Berg, Rob JW, Lane, J Robert D, Miltenburg, Andre MM, and Timmers, C Marco more...
- Subjects
- *
BIOCHEMICAL mechanism of action , *THYROTROPIN receptors , *ALLOSTERIC regulation , *GRAVES' disease , *IMMUNOGLOBULINS , *THYROID eye disease , *AUTOIMMUNE diseases - Abstract
BACKGROUND AND PURPOSE Graves' disease (GD) is an autoimmune disease in which the thyroid is overactive, producing excessive amounts of thyroid hormones, caused by thyroid-stimulating hormone (TSH) receptor-stimulating immunoglobulins (TSIs). Many GD patients also suffer from thyroid eye disease (Graves' ophthalmopathy or GO), as TSIs also activate TSH receptors in orbital tissue. We recently developed low molecular weight (LMW) TSH receptor antagonists as a novel therapeutic strategy for the treatment of GD and GO. Here, we determined the molecular pharmacology of a prototypic, nanomolar potent LMW TSH receptor antagonist, Org 274179-0. EXPERIMENTAL APPROACH Using CHO cells heterogeneously expressing human TSH receptors and rat FRTL-5 cells endogenously expressing rat TSH receptors, we determined the potency and efficacy of Org 274179-0 at antagonizing TSH- and TSI-induced TSH receptor signalling and its cross-reactivity at related follicle-stimulating hormone and luteinizing hormone receptors. We analysed the allosteric mode of interaction of Org 274179-0 and determined whether it is an inverse agonist at five naturally occurring, constitutively active TSH receptor mutants. KEY RESULTS Nanomolar concentrations of Org 274179-0 completely inhibited TSH (and TSI)-mediated TSH receptor activation with little effect on the potency of TSH, in accordance with an allosteric mechanism of action. Conversely, increasing levels of TSH receptor stimulation only marginally reduced the antagonist potency of Org 274179-0. Org 274179-0 fully blocked the increased basal activity of all the constitutively active TSH receptor mutants tested with nanomolar potencies. CONCLUSIONS AND IMPLICATIONS Nanomolar potent TSH receptor antagonists like Org 274179-0 have therapeutic potential for the treatment of GD and GO. [ABSTRACT FROM AUTHOR] more...
- Published
- 2012
- Full Text
- View/download PDF
10. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.
- Author
-
Zeng, X., Shaikh, F. Y., Harrison, M. K., Adon, A. M., Trimboli, A. J., Carroll, K. A., Sharma, N., Timmers, C., Chodosh, L. A., Leone, G., and Saavedra, H. I.
- Subjects
- *
RAS oncogenes , *CENTROSOMES , *GENE amplification , *MAMMARY glands , *EPITHELIAL cells , *CYCLINS , *CARCINOGENESIS - Abstract
Centrosome amplification (CA) contributes to carcinogenesis by generating aneuploidy. Elevated frequencies of CA in most benign breast lesions and primary tumors suggest a causative role for CA in breast cancers. Clearly, identifying which and how altered signal transduction pathways contribute to CA is crucial to breast cancer control. Although a causative and cooperative role for c-Myc and Ras in mammary tumorigenesis is well documented, their ability to generate CA during mammary tumor initiation remains unexplored. To answer that question, K-RasG12D and c-Myc were induced in mouse mammary glands. Although CA was observed in mammary tumors initiated by c-Myc or K-RasG12D, it was detected only in premalignant mammary lesions expressing K-RasG12D. CA, both in vivo and in vitro, was associated with increased expression of the centrosome-regulatory proteins, cyclin D1 and Nek2. Abolishing the expression of cyclin D1, Cdk4 or Nek2 in MCF10A human mammary epithelial cells expressing H-RasG12V abrogated Ras-induced CA, whereas silencing cyclin E1 or B2 had no effect. Thus, we conclude that CA precedes mammary tumorigenesis, and interfering with centrosome-regulatory targets suppresses CA. [ABSTRACT FROM AUTHOR] more...
- Published
- 2010
- Full Text
- View/download PDF
11. Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813.
- Author
-
Fleming, J L, Pugh, S, Bell, E H, Chang, S M, McElroy, J, Becker, A, Timmers, C D, Shih, H A, Ashby, L, Hunter, G K, Bahary, J P, Schultz, C J, Kavanagh, B D, Yung, W A, Robins, I, Werner-Wasik, M, and Chakravarti, A more...
- Published
- 2020
- Full Text
- View/download PDF
12. A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813.
- Author
-
Bell, E.H., McElroy, J.P., Fleming, J., Timmers, C., Chakraborty, A.R., Salavaggione, A.L., Chang, S.M., Shaw, E.G., Aldape, K., Brachman, D., Schultz, C.J., Shih, H.A., Curtis, M., Hunter, G.K., Murtha, A.D., Zhang, P., Won, M., Mehta, M.P., and Chakravarti, A. more...
- Subjects
- *
GLIOMAS , *ONCOLOGY , *TUMOR markers , *CANCER prognosis , *CANCER radiotherapy , *CLINICAL trials , *PATIENTS - Published
- 2016
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.